The short answer
The compounded GLP-1 business is over as a category. The Fifth Circuit affirmed FDA's shortage decisions on tirzepatide and semaglutide on August 27, 2026, the 503B final order is a formality with no date, and FDA has sent three waves of warning letters to telehealth marketers since September 2025. The branded GLP-1 business is enormous and growing: the Wegovy pill launched January 5 and was running above 265,000 US prescriptions a week by mid-July, Lilly's Foundayo was approved April 1, and Hims & Hers reported $753 million of second-quarter revenue on 2.9 million subscribers. The question for a founder is whether there is room in the second business for a brand that is not Hims, not Ro, and not CVS, which now sells a $29 online visit.
Our answer is yes, narrowly, and only for a specific shape of company: one that picks a patient group the big brands serve badly, keeps them past month three, and runs on fixed costs low enough that 500 patients pays the team. The rest of this post is the evidence for each part of that sentence.
What died
The price arbitrage. The founder post-mortem that circulated on r/EntrepreneurRideAlong in April 2026 (67 upvotes, 37 comments) described launching two months after Medvi and folding five months later: "The $99/month price point that drove Medvi's 250K customers is gone." It is gone because the drug is now $149 a month at the manufacturer for the pill's starting dose and $299 to $449 for Zepbound vials, and every patient can see those prices on NovoCare, LillyDirect, the CVS app and TrumpRx. A brand cannot mark up a drug the patient can buy at list from the maker.
The ad arbitrage. The same thread's comments are the clearest CAC data in public: "$5K to fast track legit script then roughly another $5k in platform fees per month, upfront legal around $3k", "$700+ CPM", "Spent 7k in ad spend. 0 conversions." Meta and Google require LegitScript certification for telehealth advertisers, branded GLP-1 ads need Meta's written authorization, compounded GLP-1 ads are mostly prohibited, and the public companies outspend everyone. What actually built Medvi, the thread's author wrote, "was cracking paid acquisition for a healthcare product on platforms that make healthcare advertising actively hostile." That crack has closed for most founders.
The no-moat storefront. Hacker News on the Medvi story: "Medvi is basically a frontend to white label telehealth services", "dropshipping GLP-1 with no moat." A brand that rents the clinicians, the pharmacy and the merchant account from one vendor and buys the patients from another owns nothing an acquirer will pay for; who owns what on a platform is the diligence version of that sentence.
What still works, with the evidence
| Model | What you sell | Price signal | Evidence it is working (Q2 to Q3 2026) |
|---|---|---|---|
| Care-plus-access membership around branded drugs | Clinical review, dose management, follow-up, refills; the manufacturer ships the drug | $99 to $149 per month (Ro $145, Hims $149, Noom Med from $39) | Hims 2.9M subscribers; WeightWatchers clinical subscribers up 56% year over year; LifeMD's new weight patients 95% branded |
| A patient group the big brands serve badly | Coverage-loss patients, Medicare Bridge patients, maintenance and lower-dose patients | $50 Bridge copay; $99 to $199 maintenance programs | Mercer: 6% of large employers dropped GLP-1 weight coverage in 2026, 5% weighing it for 2027; Medicaid down to 13 states; about 14.6% of GLP-1 users are on lower doses per Evidation |
| Adjacent verticals on the same stack | TRT, menopause and hormones, hair, sexual health | $100 to $200 per month bundles | Hims testosterone near a $100M run-rate; Wheel: patients 43 and older are now more than four in ten visits; Midi Health past a $1B valuation |
| Employer and HSA channel | Programs bought or subsidized by employers, paid with HSA cards | Per-member fees plus HSA-paid memberships | Omada: about 15% of members in GLP-1 programs, revenue up 43%; OBBBA made the telehealth HSA safe harbor permanent |
The first row is the default, and it is crowded. The second and third rows are where a new brand can be first. October is when plan documents land and a wave of patients discovers their 2027 coverage changed, which is why the coverage-loss funnel exists; the Medicare Bridge, live since July 1 at $50 a month with a prior-authorization workflow most consumer brands have not built, is covered in the Bridge operator playbook; and the maintenance vertical is the program for the patient at goal whom the big brands are trying to keep on a full dose.
Demand is being manufactured by payers, not by you
This is the part of late 2026 that founders who left the category in 2025 miss. Employers are cutting coverage for 2027 and telling employees in October and November. Medicaid programs dropped from 16 states to 13 between October and January, and MassHealth stopped covering anti-obesity drugs on July 1. NovoCare's $199 pen promo ends December 31, so January brings a price reset for patients who started on it. Every one of those events pushes a patient who was on a covered drug into a cash-pay decision, and they search for help in the week it happens. The demand is real, dated, and not created by paid social, which is exactly the kind of demand a small brand with a good page and a fast intake can win. The January surge build list is the calendar version.
The three moats that survive a $29 visit
A funnel you own. CVS, Walgreens ($49) and Amazon ($39 messaging, $59 video) have priced the visit as a loss leader for the pharmacy. You cannot compete on the visit. You can compete on the search result the patient reads before the visit, the intake that takes four minutes on a phone, and the email and text relationship that starts before the first prescription and continues after it. First-party conversion infrastructure is the long version; the short version is that a funnel inside an ad account is not a moat.
Retention infrastructure. Roughly half of GLP-1 patients stop within a year in the industry data; Wheel reported 83% retention in its weight programs in the first half of 2026 and attributes the gap to follow-up and adherence work. Month two is where the difference is made, and it is operational: refill automation, side-effect triage, dose changes without re-intake, a portal that answers "where is my prescription" before the patient asks. Those are features of infrastructure, not of marketing, and the month-two churn playbook shows the mechanics.
Unit cost. Hims said on its August 10 call that AI now handles about 80% of support questions. A 500-patient brand cannot build that, but it can run on a platform where order status, refills, messaging and billing are one system so that one coordinator covers 500 patients instead of two hundred. The margin math shows a $149 program netting about $40,000 a month at 500 patients on a flat-fee platform, and the same program going negative at 100 patients if it carries a self-assembled stack's tooling and build cost.
Why lower fixed cost changes "too late"
Two years ago the question was whether you could afford to reach national scale before the money ran out, because the stack cost the same whether you had 100 patients or 10,000. That is the world in which "too late" was the right question. The platform category changed the arithmetic: when storefront, intake, provider routing, approval-gated billing, pharmacy routing and portal ship as one configured system, a brand can be profitable at a few hundred patients in one niche, in a handful of states, and never need to be national. We build Turbopills for exactly that founder, and the honest caveat is that we are in private beta and quote per program, so run our numbers through the margin post before taking the previous sentence on faith.
Our opinion, stated as one: we would rather help a founder launch a 500-patient brand for coverage-loss patients in six states than a national GLP-1 brand competing with CVS on the visit price. The first can be a good business by spring. The second is a fundraising plan.
FAQ
Is it too late to start a GLP-1 telehealth business? Too late for the compounded-drug, paid-social model that worked in 2024; the Fifth Circuit ended the shortage litigation on August 27, 2026, and manufacturer cash prices set the ceiling. Not too late for a niche brand that sells care and follow-up around branded drugs, targets patients the large brands serve badly (coverage-loss, Medicare Bridge, maintenance), and runs on low fixed costs.
Can anyone start a GLP-1 program? The business can be founded by a non-clinician, but a licensed physician must own the professional entity in corporate-practice-of-medicine states, prescribing must be done by licensed providers in the patient's state, and advertising on Meta and Google requires LegitScript certification. The structure is explained in the MSO and friendly-PC post.
How much does it cost to start a GLP-1 telehealth business in 2026? Legal and clinical setup runs from the low tens of thousands (professional corporation, MSO agreements, medical director, insurance, LegitScript), plus a first-quarter ad budget. The self-assembled technology stack adds $60,000 to $250,000; a platform replaces that with a monthly fee. The line items are in the launch budget post.
What GLP-1 niche is still open? Coverage-loss patients entering open enrollment, Medicare beneficiaries using the $50 Bridge, maintenance and lower-dose programs for patients at goal, and adjacent hormone programs (TRT, menopause) that share the same infrastructure. All four are supported by dated 2026 evidence rather than ad-spend arbitrage.